Publications by authors named "Indeg Sly"
Introduction: Health economics models are typically built in Microsoft Excel owing to its wide familiarity, accessibility and perceived transparency. However, given the increasingly rapid and analytically complex decision-making needs of both the pharmaceutical industry and the field of health economics and outcomes research (HEOR), the demands of cost-effectiveness analyses may be better met by the programming language R.
Objective: This case study provides an explicit comparison between Excel and R for contemporary cost-effectiveness analysis.
Background: Human monoclonal antibody ustekinumab is a novel Crohn's disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study's objective was to assess cost-effectiveness of ustekinumab in moderate to severely active CD in Sweden.
Methods: A cost-effectiveness model with an induction phase decision-tree structure and a maintenance phase Markov cohort structure was constructed.